We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+14.32%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$889M
AUM Growth
-$164M
Cap. Flow
-$239M
Cap. Flow %
-26.87%
Top 10 Hldgs %
50.84%
Holding
103
New
31
Increased
13
Reduced
14
Closed
37

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$27.8M
2
MDT icon
Medtronic
MDT
+$25.2M
3
COO icon
Cooper Companies
COO
+$10.7M
4
DXCM icon
DexCom
DXCM
+$9.85M
5
FMS icon
Fresenius Medical Care
FMS
+$8.86M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$43.3M
2
HUM icon
Humana
HUM
+$28M
3
UHS icon
Universal Health Services
UHS
+$24M
4
BDX icon
Becton Dickinson
BDX
+$17.5M
5
CI icon
Cigna
CI
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVTY icon
51
Revvity
RVTY
$12.9B
$3.83M 0.43%
+30,000
New +$3.53M
ETNB
52
DELISTED
89bio
ETNB
$3.7M 0.42%
500,000
+50,000
+11% +$420K
MYGN icon
53
Myriad Genetics
MYGN
$308M
$3.42M 0.39%
+125,000
New +$3.38M
FATE icon
54
Fate Therapeutics
FATE
$319M
$3.41M 0.38%
975,000
+125,000
+15% +$486K
PLRX icon
55
Pliant Therapeutics
PLRX
$63.8M
$3.36M 0.38%
+300,000
New +$3.75M
NGNE icon
56
Neurogene
NGNE
$714M
$2.94M 0.33%
70,000
– –
TERN
57
DELISTED
Terns Pharmaceuticals
TERN
$2.5M 0.28%
+300,000
New +$2.47M
SRRK icon
58
Scholar Rock
SRRK
$6.34B
$2.2M 0.25%
275,000
-125,000
-31% -$1.1M
CABA icon
59
Cabaletta Bio
CABA
$455M
$2.12M 0.24%
450,000
+25,000
+6% +$145K
NTLA icon
60
Intellia Therapeutics
NTLA
$1.68B
$2.06M 0.23%
+100,000
New +$2.31M
QURE icon
61
uniQure
QURE
$3.12B
$1.97M 0.22%
+400,000
New +$2.6M
GEHC icon
62
GE HealthCare
GEHC
$32.9B
$1.88M 0.21%
+20,000
New +$1.68M
STAA icon
63
STAAR Surgical
STAA
$1.24B
$1.86M 0.21%
+50,000
New +$1.86M
TNGX icon
64
Tango Therapeutics
TNGX
$4.44B
$1.54M 0.17%
+200,000
New +$1.91M
RZLT icon
65
Rezolute
RZLT
$445M
$1.21M 0.14%
+250,000
New +$1.15M
KYTX icon
66
Kyverna Therapeutics
KYTX
$488M
$978K 0.11%
+200,000
New +$1.54M
AMGN icon
67
Amgen
AMGN
$224B
– –
-40,000
Closed -$12.5M
APGE icon
68
Apogee Therapeutics
APGE
$10.2B
– –
-80,000
Closed -$3.15M
BDX icon
69
Becton Dickinson
BDX
$49.4B
– –
-75,000
Closed -$17.5M
CI icon
70
Cigna
CI
$72.4B
– –
-50,000
Closed -$16.5M
CRBP icon
71
Corbus Pharmaceuticals
CRBP
$184M
– –
-100,000
Closed -$4.53M
DNLI icon
72
Denali Therapeutics
DNLI
$3.95B
– –
-325,000
Closed -$7.55M
DYN icon
73
Dyne Therapeutics
DYN
$4.99B
– –
-100,000
Closed -$3.53M
EDIT icon
74
Editas Medicine
EDIT
$453M
– –
-675,000
Closed -$3.15M
ELAN icon
75
Elanco Animal Health
ELAN
$11.4B
– –
-450,000
Closed -$6.49M
1 2
3
4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Integral Health Asset Management held 103 positions worth $889M, down 16% from $1.05B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Integral Health Asset Management withdrew a net $239M in Q3 2024, closing 37 positions and reducing 14 holdings. Its most notable exit was Elevance Health, an estimated $43.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

Against the trend, Integral Health Asset Management opened a new position in Inspire Medical Systems worth $33.8M.

  • Integral Health Asset Management's largest Q3 2024 buy was Inspire Medical Systems: 160,000 shares worth $33.8M.
  • Integral Health Asset Management added most to Keros Therapeutics in Q3 2024, an estimated $5.68M increase.
  • Integral Health Asset Management's biggest Q3 2024 reduction was Cytokinetics, cutting an estimated $13.9M.
  • Integral Health Asset Management fully exited Elevance Health in Q3 2024, selling an estimated $43.3M.
  • Integral Health Asset Management's ten largest holdings make up 51% of its $889M portfolio in Q3 2024.
  • Integral Health Asset Management opened 31 new positions and closed 37 in Q3 2024.
  • Integral Health Asset Management's portfolio value fell 16% quarter-over-quarter to $889M.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.